Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Give it a few days for story to hit the wires...I decided we will be at 36 by end of June. Then let's talk about a deal.
Sorry Ziggy. I just basically said the thing but you said it first. As many post as there are today, let's see if they need to hire someone or contract someone to keep up with us. LOL
I think the company is reading this board and are pulling them down because we are taking away their glory. They will most likely add after they PR the event.
Good point McMagyar. The placebo effect would most likely wear off in a day because they wouldn't remember they even took a pill (placebo or not). So, if there is efficacy then this should be approved already. Time wasted is life's wasted.
Pin this message. I would add Aussie conditional approval based on prelim efficacy.
Pretty impressive chart!!!
Let's get this moving on the next phase already. Too many life's at stake and Medicare could use the savings from the Benedict of an early approval. Let's put the 21st century cures act to work already. Also, one would think the Aussie government has seen the Ern news story so why aren't they all over Missling to get this moving.
Maybe it will lead to a settlement. I'm sure J&J wants to be done with this "Nit".
Thank you Burr. Hopefully the person asking the question will get his following to go in deep.
I missed the conference call and I don't see the playback yet. Anything worth mentioning? Any good Q&A?
Why was it removed is the question...If the data was changing then why not just leave it alone and keep the placeholder until the last day and then add the additional data? It would. Be interesting to see if another poster takes its place. If so, then we know it was a permanent removal.
I just find it hard to believe it will not present the 15 month data. If it is dropped and nothing else is said then we go nowhere until such time we here something profound (the trial starting, partnership,etc).
So far it doesn't seem like it's a big deal. Maybe a few weak longs selling.
If they take that 21,000 block, on the offer, at 5.80 then it will happen.
Don't you just sense it...that we are the verge to blow through to the 6's. If there is a tute buying here they will gobble all they can in the 5.80's. They can easily pick up 200k+ shares before end of day. I think they will make their move around 3:30
Earlier in the day, level two was showing a lot of orders for sale in the 5.70 to 5.79 range. Looking at it now, it looks like they moved them up to the 5.80's. The 5.80 to 5.82 will be a hurdle so it appears.
It goes to show if we have any great news (i.e. Reverses AD) we should shoot up 20x.
I suspect buying will heat up by end of day with 1M+ shares traded. Just a gut feel.
And 7 seconds before that 10,000 traded at 5.70.
I think we hit 6.14 before we hit 5.17. I'm not s chartist. Just strictly emotions.
Thanks Talon. Nice read. 2+ months down and 9 1/2 months remaining in 2017.
Once we get EU approval/partner, I say our share price will jump to mid 30's....I know, I know, I'm jump pumping.
And perhaps the tip of the iceberg comment.
They got it last year at this time.
Great neiu,
I like the last sentence of the first link....Furthermore, we suggest that AF710B has potential both for prevention of neurodegeneration and the deleterious neuroinflammation in AD.
nferna,
pure speculation on my part...Could the EU submission be part of the late breaking presentation?
If not, submission should be very close and if late breaking is signaling phenomenal trial results, then I believe the EU would act quickly.
Here is their note on the revenue. I expect it to be the same going forward (for at least the next 4 quarters) assuming no addition deals, etc.
During the quarter ended January 31, 2017, the Company recorded revenue of $3,790,842. The Company recognized $3,540,842 of revenue from the collaboration agreement with Amgen related to amortization of the upfront fees received. In addition, $250,000 of revenue was due to the receipt of an annual exclusive license fee from GBP for the development and commercialization of Axalimogene filolisbac.
Here are my dots from the 10Q...
Dot #1
In October 2016, upon review of these findings, the Company announced early closure of GOG-0265. Based on these data, the Company plans on pursuing regulatory opportunities for this unmet medical need in Europe in 2017, and is planning to initiate a Phase 3 registrational trial in 2017 in the metastatic cervical cancer setting. Results from the GOG-0265 study will be presented at the Society of Gynecologic Oncology (“SGO”) meeting on March 14, 2017 and was selected for an oral late-breaker presentation...IMO, late beaking means phenomenal success and thus the note above regarding EU submission.
Dot #2
Laboratory costs were $1,269,731 for the three months ended January 31, 2017 compared to $251,688 for the three months ended January 31, 2016, an increase of $1,018,043. An increase in headcount and the expansion of laboratory space accounted for the increase...Gearing up for commercial production?
Dot #3
Other expenses were $333,303 for the three months ended January 31, 2017 compared to $144,218 for the three months ended January 31, 2016, an increase of $189,085. The increase was due to additional infrastructure costs incurred to support the increased headcount and laboratory expansion....Why increased headcount if just for trial related activities? The job descriptions for the new positions have a commercialzation flair to it.
Dot #4
We anticipate a significant increase in research and development expenses as a result of our intended expanded development and commercialization efforts primarily related to clinical trials and product development. In addition, we expect to incur expenses in the development of strategic and other relationships required to license, manufacture and distribute our product candidates when they are approved...Did I say commercialization?
If we do obtain EU approval, I certainly hope the POTUS does allow money held outside the U.S. to come back in. If by chance we can't bring it back(without stiff fees), then there may be a need to dilute further to continue our aggressive agenda (assuming no domestic partners).
Perhaps the powers to be have come to the same conclusion and thus did everything they could to beat the share price down in order to accumulate on the cheap.
If we do obtain EU approval, then our share price should reflect U.S. approval as well since it is just a matter of time.
BTW, What is the potential for this market?
These are just my thoughts and opinion so please draw your conclusions.
Ignatius,
Basically, ADXS received payment for work not yet performed (think of it as an obligation to be completed). As the work is performed the liability is reduced and recognized as revenue.
Make sense?
Cattdogg, I'm hoping for the same thing. If you read the 10Q (towards the bottom) it is hard not to imagine that EU approval is very very close to fruitition for GOG-0265 and coupled with late breaking news about the trial outcome it's hard not to think of EU approval.
There are a lot of dots to connect and the picture I am seeing is EU approval very soon. I will post what I think are the dots shortly. The dots are statements from the 10Q so I'm not making this stuff up. Only thing I'm speculating is EU approval very soon (within 60 days). Just my hunch.
One can expect the revenue stream to continue since ADXS is reporting appx 14m in deferred revenue in the current liability section of the balance sheet. To be listed as current the expectations is, it will be recognized within a 12 month period.
The revenue this month is from Amgen and GPB
Also, the revenue should not come as a surprise since last quarters balance sheet had deferred revenues at around 12m+. This equates to 3M+ per quarter.
What should drive the share price next week is what comes out of the late breaking presentation on Tuesday.
It's time to move upward!!
Ziggy. At least it was the cloths closet and not the water closet. Youth is wasted on the young.
I'm not much of a chartist but if I had to bet I would say today's 5.17 low is it and we begin the march upward. I think you're thinking it's the beginning of wave four.
Ditto that. I have you Jimmy and your family in my prayers.
Ziggy. Got it. Now that you mentioned it I remember that was the case.
On another note, dang I need the drug. My wife laughed at me when after pouring milk in a glass I returned the milk to the glass cabinet instead to the refrigerator.
Brich, if you use fidelity, do a quote on AVXL and towards the bottom it list shortable shares. Click on it and it will show you the loan rate.
I had some shares returned (8,700) and paying 15.5%.
Thank you waxman
brich - not true
Fidelity is still paying me 15.5% and the borrowed rate is down but still at 25.75%
Tom123 - Do you think can call the bottom of this wave at 5.17?
Bourbon. That's pretty dang funny. Pat Banatar's comes to mind...Hit me with you best shot. Fire away.
Xenia thank you. I thought the extension was for one year. Three years make sense.
Thank power
Are you saying the original group went off the treatment after the 52 weeks and started back up in September? I was under the impression the additional 52 weeks started on the heels of the first one ending. If that is the case, I wonder what the charts would look like after a six month stop/start.
I also thought the 52 week extension was to buy the company time to start the phase 2/3 and thinking the next phase would start before the end of the 52 week extension. If the next phase doesn't start soon should we be expecting another extension due to patients/caregivers concern just like the first extension?